Panduratin A is a natural chalcone derivative with inhibitory activity against MMP-9 in human oral epidermoid carcinoma KB cells; inhibitory activity against the NS3 protease of DENV-2 (Ki=25 μM); significant cytotoxicity against human androgen-independent prostate cancer cells PC-3 and DU-145; and also able to activate the LKB1-AMPK- PPARα /δ signaling pathway and enhance the oxidative capacity of myocyte mitochondria.

A549 cells:6.26 μM, Calu-1 cells:3.98 μM, H1299 cells:4.73 μM

Panduratin A exhibited potent antiproliferative effects in multiple human lung cancer cell lines (A549, H1299, Calu-1), with IC₅₀ values after 72 hours of treatment being 6.26, 4.73, and 3.98 μM, respectively. In A549 cells, Panduratin A (2.5–10 μM) induced dose-dependent apoptosis, G0/G1 arrest, mitochondrial membrane depolarization, and increased ROS levels within 48 hours. Panduratin A also suppressed activation of PI3K/AKT and MAPK pathways[1].

In A549 xenograft-bearing mice, oral administration of Panduratin A at 25 mg/kg once daily for 14 days significantly suppressed tumor growth by approximately 55% without affecting body weight or causing observable toxicity. Tumor tissues showed increased Bax, decreased Bcl-2, and enhanced cleaved caspase-3 expression, confirming its pro-apoptotic mechanism[1].